Clinical Trials on rrMM in New Zealand
Total 10 results
-
Regeneron PharmaceuticalsActive, not recruitingRelapsed and Refractory Multiple Myeloma (RRMM)United States
-
BayerCompletedRelapsing Remitting Multiple Sclerosis (RRMS)China, Slovakia, France, Germany, Korea, Republic of, Saudi Arabia, Singapore, Sweden, Taiwan, Colombia, Czech Republic, Estonia, Italy, Jordan, Lebanon, Mexico, Slovenia, United Kingdom, Argentina, Bahrain, Egypt, United Arab Emirates and more
-
TakedaTerminatedRelapsed and/or Refractory Multiple Myeloma (RRMM)United States, Canada
-
Regeneron PharmaceuticalsRecruitingRelapsed Refractory Multiple Myeloma (RRMM)Canada, United States, Korea, Republic of, Israel, Spain, Australia, Brazil, United Kingdom, Poland, Taiwan, Singapore, France, Italy
-
Icahn School of Medicine at Mount SinaiWithdrawnRelapsing-remitting Multiple Sclerosis (RRMS)United States
-
GenmabRecruitingAcute Myeloid Leukemia (AML) | Diffuse Large B Cell Lymphoma (DLBCL) | Relapsed or Refractory Multiple Myeloma (RRMM)United States, Korea, Republic of, Netherlands, Denmark, Australia, New Zealand, Poland, Spain, Sweden, Czechia, Malaysia, Greece, Moldova, Republic of, Georgia, Ukraine, France, Hungary, North Macedonia, Bosnia and Herzegovina
-
Novartis PharmaceuticalsCompletedMultiple Sclerosis | RRMSSpain, Czechia, Germany, Australia, Italy, Switzerland, Denmark, United States, United Kingdom, Canada, Netherlands, Poland
-
Novartis PharmaceuticalsTerminatedRelapsing-remitting Multiple Sclerosis (RRMS)United States, Canada, Mexico, Brazil, Puerto Rico, Argentina, Chile
-
BiogenRecruiting
-
Karyopharm Therapeutics IncActive, not recruitingAcute Myeloid Leukemia (AML) | Metastatic Colorectal Cancer (mCRC) | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Relapsed/Refractory Multiple Myeloma (RRMM) | Higher-Risk Myelodysplastic Syndrome (HR-MDS) | Newly Diagnosed Intermediate/High-Risk MDSUnited States, France, Canada, Spain, China